Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review
Authors' conclusion
The level of evidence of the studies included in this review was low and the quality generally poor.
Study context
- Population
- Case studies, case series, cross-sectional, case-control and cohort studies reporting patients with an incident inflammatory rheumatic musculoskeletal disease (iRMD) following COVID-19 (search until August 2022)80 studies
- Outcome
- Association between acute COVID-19 and subsequent iRMD diagnosis
Methodological detailssystematic search of Medline, EMBASE and two COVID-19 databases, narrative synthesis, Title and abstract screening by one reviewer, full text screening by two reviewers; data extraction and quality appraisal by one reviewer, verified by a second
- Systematic search of Medline, EMBASE and two COVID-19 databases
- Narrative synthesis
- Title and abstract screening by one reviewer, full text screening by two reviewers; data extraction and quality appraisal by one reviewer, verified by a second
Main finding
As reported in the abstract
Commonly reported incident iRMDs after COVID-19
- Reactive arthropathies (n)
- 47
- Inflammatory arthropathies unspecified (n)
- 18
- RA (n)
- 12
- SLE (n)
- 11
- Cross-sectional study: those with COVID-19 developing post COVID arthritis
- 37%
- Time from COVID-19 diagnosis to iRMD presentation (days)
- 0 to 120
Original publication
Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review. Arthritis Care Res (Hoboken). Published 23 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →